Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It also expects its 2024 sales to rise in ...
No guidance is provided about conversion of dates before March 5, -500, or after February 29, 2100 (both being Julian dates). For unlisted dates, find the date in the table closest to, but earlier than, the date to be converted. Be sure to use the correct column. If converting from Julian to Gregorian, add the number from the "Difference" column.
All examples use example date 2021-03-31 / 2021 March 31 / 31 March 2021 / March 31, 2021 – except where a single-digit day is illustrated. Basic components of a calendar date for the most common calendar systems: D – day; M – month; Y – year; Specific formats for the basic components: yy – two-digit year, e.g. 24; yyyy – four-digit ...
GSK would share additional data with U.S. agencies by the end of this year, she said. Citing the U.S. agency's decision, GSK cut its forecast for 2024 vaccine sales.
March 1, 2024 at 11:04 AM (Reuters) -GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British ...
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. It is also approved in Europe ...